---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-050830"
form_type: "8-K"
ticker: "MGRX"
cik: "0001938046"
company_name: "MANGOCEUTICALS, INC."
filed_at: "2024-12-19T23:59:59+00:00"
generated_at: "2026-05-29T01:48:28.410459+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Mangoceuticals acquires mushroom patent for 515k shares; CEO Cohen secures 75.5% voting control of subsidiary M&P

## Summary
- Acquired mushroom patent WO 2023/086647 from Greenfield Investments for 515,000 restricted shares of common stock.
- Contributed substantially all assets (MangoRx Mexico and UK) to new subsidiary Mango & Peaches Corp.
- CEO Jacob Cohen received 1.7M common shares (25.4%) and Series A preferred with 51% voting power, totaling 75.5% voting control of M&P.
- CEO base salary raised to $360k/year; severance increased to 3x salary plus target bonus; term extended to Dec 2027.
- Granted Greenfield a co-exclusive license to patents for 10% royalty on gross sales starting Dec 2025.

## SEC filing metadata
- accession: 0001493152-24-050830
- form_type: 8-K
- ticker: MGRX
- cik: 0001938046
- company_name: MANGOCEUTICALS, INC.
- filed_at: 2024-12-19T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 1.01, 5.02, 2.01, 3.02, 3.03, 5.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1938046/000149315224050830/0001493152-24-050830-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1938046/000149315224050830/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-050830
- JSON: https://secwatch.observer/filing/0001493152-24-050830.json
- Plain text: https://secwatch.observer/filing/0001493152-24-050830.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.